Atara Biotherapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers the 2020 Annual Meeting of Stockholders held by Atara Biotherapeutics, Inc. on June 16, 2020. The filing details the voting results for director elections, executive compensation, and the ratification of the independent auditor.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.
Material Changes and Voting Results
The following matters were submitted to a vote of security holders:
- Election of Directors: Both nominees, Pascal Touchon, D.V.M., and Carol Gallagher, Pharm.D., were elected to serve until the 2023 annual meeting.
- Pascal Touchon: 43,309,203 votes For; 4,398,437 votes Withheld.
- Carol Gallagher: 36,658,749 votes For; 11,048,891 votes Withheld.
- Advisory Vote on Executive Compensation: Stockholders approved the compensation of named executive officers.
- For: 29,808,000
- Against: 15,489,277
- Abstain: 2,410,363
- Ratification of Independent Auditor: Stockholders ratified the appointment of Deloitte & Touche LLP for the fiscal year ending December 31, 2020.
- For: 54,737,941
- Against: 43,707
- Abstentions: 67,336
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. For detailed risk factors and management discussion, investors should refer to the definitive proxy statement filed on April 22, 2020.
Key Facts for Investor Verification
- Verify the full text of the April 22, 2020 Proxy Statement for detailed context on executive compensation and director qualifications.
- Note the significant number of votes withheld for Carol Gallagher (11,048,891) compared to Pascal Touchon (4,398,437).
- Confirm the split in the advisory compensation vote, where approximately 34% of votes cast were against the proposal.
- Review the company's most recent 10-K or 10-Q for financial performance data, as this 8-K contains no financial metrics.